对 Frederic Bretzner 等人的回应：“在脊髓损伤中进行首例人类胚胎干细胞研究的目标人群”。

Response to Frederic Bretzner et al. "Target populations for first-in-human embryonic stem cell research in spinal cord injury".

机构信息

Geron Corporation, Menlo Park, CA 94025-1109, USA.

出版信息

Cell Stem Cell. 2011 May 6;8(5):476-8. doi: 10.1016/j.stem.2011.04.008.

DOI:10.1016/j.stem.2011.04.008

Abstract

We address concerns raised in this issue by Bretzner et al. (2011) by explaining the rationale for including subjects with subacute, neurologically complete spinal cord injuries in the Phase 1 trial of GRNOPC1. We also present elements of the informed consent process that minimize the likelihood of therapeutic misconception.

摘要

我们通过解释在 GRNOPC1 一期临床试验中纳入亚急性、神经完全性脊髓损伤患者的基本原理，来回应 Bretzner 等人（2011 年）提出的关切。我们还介绍了知情同意过程中的一些要素，以最大程度地降低治疗误解的可能性。